The requested research item does not exist. Please return to Research
In the new reality for life sciences companies – one where the product development formula of the past no longer applies, where extensive M&A activity is needed to fill pipelines and mitigate risk, and where an increasing amount of attention and opportunity lie in emerging markets – prudent measures and strategic solutions are critical to succeed. More than ever, it is essential to achieve the ideal portfolio balance, with the proper size and type of facilities in the right locations.
Please fill out the form to download the report.
Monday, January 14, 2013